News | August 06, 2025
Indegene posts Q1 net profit higher by 33% YoY to Rs. 116.4 Cr
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
EBITDA before special items decreases to €4.08 billion (7.4%)
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Delivers robust earnings performance, successfully navigating a dynamic environment
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring
Subscribe To Our Newsletter & Stay Updated
